Open access
Preclinical and First‐In‐Human Evaluation of Ribupatide (HRS9531), a Dual GLP‐1/GIP Receptor Agonist
K. He
Yi-Lin Wei
Heng-Li Zhao
Lian-Shan Zhang
Fang-Zhou Wu
Ren-Zhi Liu
Yan-Yan Zhang
Y. Wang
Hong Chen
Mei-Fang Zeng
Li-Gong Zhi
Tian-Lin Zhou
Zhen Sheng
Qing Wen
Sep 2026 · Diabetes, obesity and metabolism · Vol 28, pp. 11643 - 11652 · 0 citations
· 24 references
Medicine
Abstract
This study assessed the preclinical and clinical pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of ribupatide (HRS9531), a novel dual agonist of glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptors.